PolyPeptide Group AG
PPGN
Rank in Stocks
#6689
PolyPeptide Group AG operates globally as a contract development and... PolyPeptide Group AG operates globally as a contract development and manufacturing organization (CDMO), specializing in the production of Good Manufacturing Practice (GMP)-grade peptides. These peptides, available in both proprietary and generic forms, are vital for pharmaceutical and biotechnology companies, serving as key ingredients in approved medicines, compounds undergoing clinical development, and generic drug formulations. The company also produces custom research-grade peptides and actively develops neoantigen peptides to support personalized cancer therapies. Its manufacturing expertise extends to peptides used in commercially approved therapeutics, peptide-based generics for human and veterinary applications, and cosmetic peptides. Additionally, PolyPeptide Group AG provides regulatory affairs support services. Founded in 1952 and headquartered in Zug, Switzerland, the company is a subsidiary of Draupnir Holding B.V.
Share Price
$49.22
Last synced: 2026-11-09
Market Cap
$1.63B
Change (1 day)
0.71%
Change (1 year)
63.82%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade PolyPeptide Group AG (PPGN)
Category
Healthcare
EPS for PolyPeptide Group AG (PPGN)
EPS as of June 2026 TTM: $0.48
According to PolyPeptide Group AG's latest financial reports, its current EPS (TTM) is $0.48. At the end of 2025 the company had an EPS of $-0.75, a decrease compared to its 2024 EPS of $-0.61.
EPS history for PolyPeptide Group AG from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.48 | -163.93% |
| 2025 | $-0.75 | 22.32% |
| 2024 | $-0.61 | -64.40% |
| 2023 | $-1.72 | -769.97% |
| 2022 | $0.26 | -84.60% |
| 2021 | $1.67 | 31.98% |
| 2020 | $1.27 | 31.27% |
| 2019 | $0.96 | 6.29% |
| 2018 | $0.91 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $6.50 | 1,255.87% |
DE
|
|
| $6.08 | 1,167.49% |
DE
|
|
| $1.55 | 223.38% |
JP
|
|
| $3.66 | 663.30% |
CH
|
|
| $0.45 | -6.15% |
IL
|
Questions about PolyPeptide Group AG's earnings per share (EPS)
What is PolyPeptide Group AG's earnings per share (EPS)?
PolyPeptide Group AG's earnings per share (EPS) over the last twelve months is $0.48, as of Jun 2026.
What was PolyPeptide Group AG's earnings per share (EPS) in 2025?
In 2025, PolyPeptide Group AG's earnings per share (EPS) was $-0.75, compared with $-0.61 in 2024.
How has PolyPeptide Group AG's earnings per share (EPS) changed since 2020?
From 2020 to 2025, PolyPeptide Group AG's earnings per share (EPS) was highest in 2021 ($1.67) and lowest in 2023 ($-1.72).
How does PolyPeptide Group AG's earnings per share (EPS) compare with similar companies?
PolyPeptide Group AG's earnings per share (EPS) ($0.48) is higher than that of 1 of the 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.50.